Improved Outcomes of Thermal Ablation for Colorectal Liver Metastases: A 10-Year Analysis from the Prospective Amsterdam CORE Registry (AmCORE)

Puijk, Robbert S.; Dijkstra, Madelon; Bemd, Bente A. T. van den; Ruarus, Alette H.; Nieuwenhuizen, Sanne; Geboers, Bart; Timmer, Florentine E. F.; Schouten, Evelien A.C.; Vries, Jan J. J. de; Meijs, Bram B. van der; Nielsen, Karin; Swijnenburg, Rutger-Jan; Tol, M.P. van den; Versteeg, Kathelijn S.; Lissenberg‐Witte, Birgit I.; Scheffer, Hester J.; Meijerink, Martijn R.

doi:10.1007/s00270-022-03152-9

Cited by 23 publications

(20 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 Additionally, select literature has compared percutaneous approaches to open—not minimally invasive—surgical ablations, with obvious between-group differences for those cohorts. 39 Our group performs laparoscopic MWA on an outpatient basis, significantly reducing the cost differential between surgical and percutaneous approaches with low morbidity. One final point is that a substantial degree of ablation literature incorporates RFA; surgeons and interventional radiologists must reliably report their outcomes to ensure that prior studies and opinions remain supported by data now that MWA has supplanted RFA as the primary hepatic ablation modality.…”

Section: The Decision-making Processmentioning

confidence: 99%

A Review of Resection and Surgical Ablation for Primary and Secondary Liver Cancers

White,

Jensen,

Brauer

2023

Semin intervent Radiol

View full text Add to dashboard Cite

The surgical management of primary and secondary liver tumors is constantly evolving. Patient selection, particularly with regard to determining resectability, is vital to the success of programs directed toward invasive treatments of liver tumors. Particular attention should be paid toward determining whether patients are best served with surgical resection or ablative therapies. A multidisciplinary approach is necessary to provide optimal care to patients with liver malignancy.

show abstract

Section: The Decision-making Processmentioning

confidence: 99%

A Review of Resection and Surgical Ablation for Primary and Secondary Liver Cancers

White,

Jensen,

Brauer

2023

Semin intervent Radiol

View full text Add to dashboard Cite

show abstract

“…The open or percutaneous approach to thermal ablation has been studied in the literature. Puijk et al., reported significantly improving liver tumor PFS following percutaneous ablation (2010-2013: 37.7%; 2014-2017: 69%; 2018-2021: 86.3%; P< 0.0001) whereas the PFS was stable following open ablations (2010-2013: 87.1%; 2014-2017: 92.7%; 2018-2021: 90.2%; P= 0.12) ( 56 ). The complications were less severe in percutaneous rather than open approach (2010-2013: P=0.69; 2014-2017: P= 0.129; 2018-2021: P= 0.02) ( 56 ).…”

Section: Therapies With Curative Intentmentioning

confidence: 99%

“…Puijk et al., reported significantly improving liver tumor PFS following percutaneous ablation (2010-2013: 37.7%; 2014-2017: 69%; 2018-2021: 86.3%; P< 0.0001) whereas the PFS was stable following open ablations (2010-2013: 87.1%; 2014-2017: 92.7%; 2018-2021: 90.2%; P= 0.12) ( 56 ). The complications were less severe in percutaneous rather than open approach (2010-2013: P=0.69; 2014-2017: P= 0.129; 2018-2021: P= 0.02) ( 56 ). The tissue damage secondary to ablation is low when compared to surgical resection, which is the most important requisite in patients with underlying liver disease or those who already had extensive liver resection ( 55 ).…”

Section: Therapies With Curative Intentmentioning

confidence: 99%

Interventional radiological therapies in colorectal hepatic metastases

Vulasala,

Sutphin,

Kethu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Colorectal malignancy is the third most common cancer and one of the prevalent causes of death globally. Around 20-25% of patients present with metastases at the time of diagnosis, and 50-60% of patients develop metastases in due course of the disease. Liver, followed by lung and lymph nodes, are the most common sites of colorectal cancer metastases. In such patients, the 5-year survival rate is approximately 19.2%. Although surgical resection is the primary mode of managing colorectal cancer metastases, only 10-25% of patients are competent for curative therapy. Hepatic insufficiency may be the aftermath of extensive surgical hepatectomy. Hence formal assessment of future liver remnant volume (FLR) is imperative prior to surgery to prevent hepatic failure. The evolution of minimally invasive interventional radiological techniques has enhanced the treatment algorithm of patients with colorectal cancer metastases. Studies have demonstrated that these techniques may address the limitations of curative resection, such as insufficient FLR, bi-lobar disease, and patients at higher risk for surgery. This review focuses on curative and palliative role through procedures including portal vein embolization, radioembolization, and ablation. Alongside, we deliberate various studies on conventional chemoembolization and chemoembolization with irinotecan-loaded drug-eluting beads. The radioembolization with Yttrium-90 microspheres has evolved as salvage therapy in surgically unresectable and chemo-resistant metastases.

show abstract

“…If the CRLMs are primarily not eligible for local treatment, successful downstaging with induction chemotherapy can be achieved in up to 12.5% of patients. The 5-year OS increases up to 58% after local treatment of CRLMs in patients with liver only disease [ 5 , 10 , 11 , 12 , 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Local Treatment of Colorectal Liver Metastases in the Presence of Extrahepatic Disease: Survival Outcomes from the Amsterdam Colorectal Liver Met Registry (AmCORE)

Schulz,

Dijkstra,

van der Lei

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

Background: The simultaneous presence of colorectal liver metastases (CRLMs) and extrahepatic metastases in patients with colorectal cancer (CRC) can be considered a relative contraindication for local treatment with curative intent. This study aims to assess the survival outcomes of patients with CRLMs and extrahepatic metastases after comprehensive local treatment of all metastatic sites. Methods: Patients with CRLMs who received local treatment of all metastatic sites were extracted from the prospective AmCORE registry database and subdivided into two groups: CRLM only vs. CRLM and extrahepatic metastasis. To address potential confounders, multivariate analysis was performed. The primary endpoint was overall survival (OS). Results: In total, 881 patients with CRLM only and 60 with CRLM and extrahepatic disease were included, and the median OS was 55.7 months vs. 42.7 months, respectively. Though OS was significantly lower in patients with concomitant extrahepatic metastases (HR 1.477; 95% CI 1.029–2.121; p = 0.033), the survival curve plateaued after 6.2 years. Extrahepatic manifestations were pulmonary (43.3%), peritoneal (16.7%) and non-regional lymph node metastases (10.0%). In patients with pulmonary and non-regional lymph node metastases, OS did not significantly differ from patients with CRLM-only disease; concomitant peritoneal metastases showed an inferior OS (HR 1.976; 95% CI 1.017–3.841, p = 0.041). Conclusions: In this comparative series, OS was inferior for patients with multi-organ metastatic CRC versus patients with CRLMs alone. Nonetheless, the long-term survival curve plateau seemed to justify local treatment in a subset of patients with multi-organ metastatic CRC, especially for patients with CRLMs and pulmonary or lymph node metastases.

show abstract

Improved Outcomes of Thermal Ablation for Colorectal Liver Metastases: A 10-Year Analysis from the Prospective Amsterdam CORE Registry (AmCORE)

Cited by 23 publications

References 55 publications

A Review of Resection and Surgical Ablation for Primary and Secondary Liver Cancers

A Review of Resection and Surgical Ablation for Primary and Secondary Liver Cancers

Interventional radiological therapies in colorectal hepatic metastases

Local Treatment of Colorectal Liver Metastases in the Presence of Extrahepatic Disease: Survival Outcomes from the Amsterdam Colorectal Liver Met Registry (AmCORE)

Contact Info

Product

Resources

About